Publications by authors named "Michael Marcos"

Claim this Profile
E
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Priscilla A Hollander, Wendy L Carofano, Raymond L H Lam, Gregory T Golm, Roy Eldor, Michael C Marcos

Diabetes Obes Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Philip D Home, Raymond L H Lam, Wendy L Carofano, Gregory T Golm, Roy Eldor, Michael C Marcos

Diabetes Obes Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Michael F Crutchlow, John S Palcza, Kate M Mostoller, Chantal D Mahon, April M Barbour, Michael C Marcos

Diabetes Obes Metab· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haïti and the health marketplace: the role of the private, informal market in filling the gaps left by the state.
J Durham, Marcos Michael, P S Hill, E Paviignani

BMC Health Serv Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant expression and anti-microbial activity of anti-lipopolysaccharide factor (ALF) from the black tiger shrimp Penaeus monodon.
Kunlaya Somboonwiwat, Michael Marcos, Anchalee Tassanakajon, Sirawut Klinbunga, André Aumelas

Dev Comp Immunol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis